2018-08-22 16:00Financial Performance - The company's operating revenue for the current period reached RMB 14,840,014 thousand, representing a year-on-year increase of 33.51% compared to RMB 11,115,338 thousand in the same period last year[18]. - Net profit attributable to shareholders for the current period was RMB 2,619,000 thousand, a significant increase of 126.14% from RMB 1,158,140 thousand in the previous year[18]. - The total profit amounted to RMB 3,011,163 thousand, with a year-on-year increase of 115.02%[40]. - The company achieved a revenue of RMB 14,840,014 thousand, representing a year-on-year growth of 33.51%[30]. - The company's basic earnings per share of RMB 1.611, which is a 126.14% increase compared to RMB 0.712 in the same period last year[19]. - The gross profit margin for the main business decreased to 31.87%, down 5.27 percentage points year-on-year[52]. - The company reported a total comprehensive income of RMB 2,662,534,357.86 for the period, compared to RMB 1,190,136,825.20 in 2017, marking a significant increase[173]. Assets and Liabilities - Total assets at the end of the current period amounted to RMB 48,191,445 thousand, marking a 70.23% increase from RMB 28,310,301 thousand at the end of the previous year[19]. - The company's total liabilities increased significantly, with current liabilities rising by 194.43% to RMB 24,345,886 thousand compared to RMB 8,268,854 thousand at the end of 2017[58]. - The company's cash and cash equivalents amounted to RMB 13,774,438 thousand as of June 30, 2018, compared to RMB 11,495,535 thousand at the end of 2017[58]. - The asset-liability ratio as of June 30, 2018, was 54.14%, up from 31.97% at the end of 2017[70]. - The company's total liabilities as of June 30, 2018, were RMB 26.09 billion, compared to RMB 9.05 billion at the end of 2017, marking an increase of around 187.5%[170]. Investments and Acquisitions - The company completed the acquisition of a 30% stake in a pharmaceutical company, increasing its ownership to 80%[106]. - The acquisition of a 30% stake in a pharmaceutical company was completed on May 31, 2018, resulting in the company holding 80% of the subsidiary[41]. - The company has invested in various projects in the healthcare sector, including the establishment of Guangzhou Baiyunshan Hospital and other healthcare facilities, indicating a focus on market expansion[25]. - The company has made a cash investment of RMB 1,700 million in a joint venture for a medical device innovation incubation platform, with an initial contribution of RMB 340 million completed[101]. - The company plans to establish a subsidiary in Zhongshan through the acquisition of Zhuhai Anshi Pharmaceutical Co., Ltd. for RMB 250 million, with the matter still in progress[102]. Research and Development - Research and development expenses rose to RMB 242,287 thousand, an increase of 81.14% compared to RMB 133,758 thousand in the previous year, reflecting heightened investment in drug consistency evaluation and other research projects[50]. - The company established 3 provincial-level and 2 municipal-level technology centers during the reporting period, enhancing its R&D capabilities[46]. - The company applied for 29 domestic invention patents and was granted 19, indicating a strong focus on innovation[46]. Compliance and Governance - The financial report for the reporting period was prepared in accordance with Chinese accounting standards and is unaudited[4]. - The board of directors confirmed the accuracy and completeness of the financial report[3]. - The company has no violations of decision-making procedures for external guarantees[6]. - The company is actively working to ensure compliance with applicable listing rules regarding related party transactions[83]. - The company has appointed Ruihua Certified Public Accountants as its financial auditing firm for the fiscal year 2018, following the end of the engagement with Lixin CPA[86]. Market Strategy and Expansion - The company plans to focus on future development strategies, although specific commitments were not made[4]. - The company aims to enhance its market presence through strategic expansions and potential acquisitions[4]. - The company is actively pursuing market expansion through partnerships and investments in retail and logistics services[44]. - The health sector has implemented a differentiated sales strategy, accelerating market penetration and enhancing sales and brand influence[73]. Social Responsibility - The company has invested over RMB 5 million in poverty alleviation efforts, achieving a poverty alleviation rate of 80% among 367 registered poor households[110]. - The company plans to achieve a 100% poverty alleviation rate by the end of 2018, focusing on industry support and skills training for impoverished households[111]. - The company has implemented 12 poverty alleviation projects, with a total investment of RMB 81.04 million in various initiatives[109]. Environmental Compliance - The company has reported no exceedances in pollutant emissions for key pollutants such as sulfur dioxide and nitrogen oxides from its chemical pharmaceutical plant[121]. - The company has implemented effective pollution prevention facilities to ensure compliance with air and wastewater discharge standards[122]. - The company has established emergency response plans for environmental incidents and conducts regular drills[125]. Employee and Shareholder Information - The total number of employees in the group was 26,399, with a total salary expenditure of approximately RMB 1.27 billion in the first half of 2018[162]. - The company implemented a new policy to increase the starting salary for PhD graduates in 2018, aiming to enhance talent acquisition[163]. - As of June 30, 2018, the number of shareholders holding the company's stock was 58,906, with 58,881 being domestic A-share holders[142].